Skip to main content

Meridian Bioscience, Inc. (VIVO)

NASDAQ: VIVO · IEX Real-Time Price · USD
18.60 0.15 (0.81%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap805.08M
Revenue (ttm)305.85M
Net Income (ttm)71.24M
Shares Out43.33M
EPS (ttm)1.62
PE Ratio11.45
Forward PE16.23
Dividendn/a
Ex-Dividend Daten/a
Volume150,760
Open18.40
Previous Close18.45
Day's Range18.20 - 18.68
52-Week Range15.45 - 30.65
Beta0.49
AnalystsBuy
Price Target26.00 (+39.8%)
Est. Earnings DateNov 12, 2021

About VIVO

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid im...

IndustryHealth Care Equipment & Supplies
CEOJohn Kenny
Employees750
Stock ExchangeNASDAQ
Ticker SymbolVIVO
Full Company Profile

Financial Performance

In 2020, VIVO's revenue was $253.67 million, an increase of 26.19% compared to the previous year's $201.01 million. Earnings were $46.19 million, an increase of 89.43%.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for VIVO stock is "Buy." The 12-month stock price forecast is 26.00, which is an increase of 39.78% from the latest price.

Price Target
$26.00
(39.78% upside)
Analyst Consensus: Buy

News

Meridian Bioscience to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on November 12, 2021

CINCINNATI, Oct. 14, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report fourth quarter a...

1 week ago - PRNewsWire

Meridian Launches New Air-Dryable™ qPCR Mix Enabling Direct Detection of RNA from Whole Blood Samples

CINCINNATI, Oct. 7, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of...

2 weeks ago - PRNewsWire

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Stool Samples

CINCINNATI, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the addition of two ne...

1 month ago - GlobeNewsWire

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples

CINCINNATI, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new ...

1 month ago - GlobeNewsWire

Meridian Bioscience Expands Voluntary Recall of LeadCare Test Kits

Meridian Bioscience Inc's (NASDAQ: VIVO) subsidiary Magellan Diagnostics Inc has expanded the Class I recall of its LeadCare Test Kits used to detect lead in whole blood. Magellan provides two controls ...

1 month ago - Benzinga

Meridian Bioscience, Inc.: Magellan Diagnostics, Inc. Expands Voluntary Recall of LeadCare Test Kits

CINCINNATI, OH / ACCESSWIRE / September 1, 2021 / Meridian Bioscience, Inc. (NASDAQ:VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced its wholly owned sub...

1 month ago - Accesswire

Got $1,000? These 2 Bargain-Bin Biopharma Stocks Might Be Worth Buying

These healthcare stocks have their warts, but the price is right for long-term investors.

Other symbols:ATRS
1 month ago - The Motley Fool

Meridian Bioscience (VIVO) Q3 Earnings and Revenues Miss Estimates

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of -29.03% and -13.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Meridian Bioscience: Q3 Earnings Insights

Shares of Meridian Bioscience (NASDAQ:VIVO) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share decreased 60.00% year over year to $0.22, which missed the est...

2 months ago - Benzinga

Meridian Bioscience Reports Third Quarter Fiscal 2021 Results

CINCINNATI, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2021.

2 months ago - GlobeNewsWire

4 Profitable Stocks to Boost Returns Using Net Income Ratio

DAC, BYD, CMRE, VIVO, and MGY qualified the screen for the net income ratio for the day.

Other symbols:BYDCMREDACMGY
2 months ago - Zacks Investment Research

Meridian Closes Acquisition of BreathTek® Business

CINCINNATI, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it closed the prev...

2 months ago - GlobeNewsWire

Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc.

CINCINNATI, July 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a defini...

2 months ago - GlobeNewsWire

Meridian Bioscience to Hold Third Quarter Fiscal 2021 Financial Results Conference Call on August 6, 2021

CINCINNATI, July 14, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter fiscal 2021 f...

3 months ago - GlobeNewsWire

Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Meridian Bioscience (VIVO) closed at $22.05, marking a +1.61% move from the previous day.

3 months ago - Zacks Investment Research

Meridian Resubmits Application to FDA for Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay

CINCINNATI, June 28, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has re-submitte...

3 months ago - GlobeNewsWire

Meridian's New Master Mix for LAMP Assays Offers a Practical Solution for POC Molecular Detection of RNA viruses

CINCINNATI, June 16, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-R...

4 months ago - GlobeNewsWire

Meridian Bioscience to Participate in the 41st Annual William Blair Growth Stock Conference and Jefferies Virtual Hea...

CINCINNATI, May 27, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today participation in two upcoming investor conferences. Jack Kenny, Chief Executive Officer, will partic...

4 months ago - GlobeNewsWire

Meridian Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples

CINCINNATI, May 17, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Ai...

5 months ago - GlobeNewsWire

Meridian Bioscience (VIVO) Beats Q2 Earnings Estimates

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 16.67% and -2.26%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in Second Quarter Fiscal 2021

CINCINNATI, May 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021.

5 months ago - GlobeNewsWire

Meridian Bioscience (VIVO) Reports Next Week: Wall Street Expects Earnings Growth

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Meridian Bioscience (VIVO) Dips More Than Broader Markets: What You Should Know

Meridian Bioscience (VIVO) closed at $20.76 in the latest trading session, marking a -1.66% move from the prior day.

5 months ago - Zacks Investment Research

Meridian Simplifies Workflows for POC Molecular Tests with a New Lyo-Ready™ LAMP Mix

CINCINNATI, April 28, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-...

5 months ago - GlobeNewsWire